PERITONEAL FLUID MESOTHELIN CONCENTRATION AND MENOPAUSAL STATUS OF PATIENTS WITH OVARIAN CANCER

The aim of the analysis was for the first time to assess the expression of genes encoding IL-21 and IL-22 at the mRNA level in ovarian tumor specimens and the concentration of these parameters in serum and peritoneal fluid in patients with ovarian serous cancer. The levels of IL-21 and IL-22 transcripts were evaluated with the use of the real-time RT-qPCR. Enzyme-linked immunosorbent assay (ELISA) was used to determine the concentration of proteins. Quantitative analysis of IL-21 gene mRNA in the tumor tissue showed the highest activity in the G1 degree of histopathological differentiation and was higher in G1 compared to the control group. The concentration of IL-21 and IL-22 in the serum and in the peritoneal fluid of women with ovarian cancer varied depending on the degree of histopathological differentiation of the cancer and showed statistical variability compared to controls. The conducted studies have shown that the local and systemic changes in the immune system involving IL-21 and IL-22 indicate the participation of these parameters in the pathogenesis of ovarian cancer, and modulation in the IL-21/IL-22 system may prove useful in the development of new diagnostic and therapeutic strategies used in patients, which require further research.

Download Full-text

BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer

Genes ◽

10.3390/genes12070969 ◽

2021 ◽

Vol 12 (7) ◽

pp. 969

Author(s):

Maxim Pilyugin ◽

Magda Ratasjka ◽

Maciej Stukan ◽

Nicole Concin ◽

Robert Zeillinger ◽

...

Keyword(s):

Ovarian Cancer ◽

Early Detection ◽

Blood Test ◽

Menopausal Status ◽

Clinical Samples ◽

Average Risk ◽

Healthy Controls ◽

Cancer Antigen 125 ◽

Cancer Syndrome ◽

Ovarian Cancer Screening

Background: Ovarian cancer (OC) is the most lethal gynaecological cancer. It is often diagnosed at an advanced stage with poor chances for successful treatment. An accurate blood test for the early detection of OC could reduce the mortality of this disease. Methods: Autoantibody reactivity to 20 epitopes of BARD1 and concentration of cancer antigen 125 (CA125) were assessed in 480 serum samples of OC patients and healthy controls. Autoantibody reactivity and CA125 were also tested for 261 plasma samples of OC with or without mutations in BRCA1/2, BARD1, or other predisposing genes, and healthy controls. Lasso statistic regression was applied to measurements to develop an algorithm for discrimination between OC and controls. Findings and interpretation: Measurement of autoantibody binding to a number of BARD1 epitopes combined with CA125 could distinguish OC from healthy controls with high accuracy. This BARD1-CA125 test was more accurate than measurements of BARD1 autoantibody or CA125 alone for all OC stages and menopausal status. A BARD1-CA125-based test is expected to work equally well for average-risk women and high-risk women with hereditary breast and ovarian cancer syndrome (HBOC). Although these results are promising, further data on well-characterised clinical samples shall be used to confirm the potential of the BARD1-CA125 test for ovarian cancer screening.

Download Full-text

Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium

Endocrine Related Cancer ◽

10.1530/erc-12-0395 ◽

2013 ◽

Vol 20 (2) ◽

pp. 251-262 ◽

Cited By ~ 117

Author(s):

Catherine M Olsen ◽

Christina M Nagle ◽

David C Whiteman ◽

Roberta Ness ◽

Celeste Leigh Pearce ◽

...

Keyword(s):

Ovarian Cancer ◽

Menopausal Status ◽

Low Grade ◽

Ovarian Cancer Risk ◽

Histological Subtypes ◽

Increased Risk ◽

Modifiable Factors ◽

Menopausal Women ◽

Increase Risk ◽

Post Menopausal

Whilst previous studies have reported that higher BMI increases a woman's risk of developing ovarian cancer, associations for the different histological subtypes have not been well defined. As the prevalence of obesity has increased dramatically, and classification of ovarian histology has improved in the last decade, we sought to examine the association in a pooled analysis of recent studies participating in the Ovarian Cancer Association Consortium. We evaluated the association between BMI (recent, maximum and in young adulthood) and ovarian cancer risk using original data from 15 case–control studies (13 548 cases and 17 913 controls). We combined study-specific adjusted odds ratios (ORs) using a random-effects model. We further examined the associations by histological subtype, menopausal status and post-menopausal hormone use. High BMI (all time-points) was associated with increased risk. This was most pronounced for borderline serous (recent BMI: pooled OR=1.24 per 5 kg/m2; 95% CI 1.18–1.30), invasive endometrioid (1.17; 1.11–1.23) and invasive mucinous (1.19; 1.06–1.32) tumours. There was no association with serous invasive cancer overall (0.98; 0.94–1.02), but increased risks for low-grade serous invasive tumours (1.13, 1.03–1.25) and in pre-menopausal women (1.11; 1.04–1.18). Among post-menopausal women, the associations did not differ between hormone replacement therapy users and non-users. Whilst obesity appears to increase risk of the less common histological subtypes of ovarian cancer, it does not increase risk of high-grade invasive serous cancers, and reducing BMI is therefore unlikely to prevent the majority of ovarian cancer deaths. Other modifiable factors must be identified to control this disease.

Download Full-text

CA125 in peritoneal fluid of ovarian cancer patients

Gynecologic Oncology ◽

10.1016/0090-8258(92)90032-e ◽

1992 ◽

Vol 44 (2) ◽

pp. 161-165 ◽

Cited By ~ 13

Author(s):

Ignace B. Vergote ◽

Mathias Onsrud ◽

Ole P. Børmer ◽

Bilal M. Sert ◽

Mette Moen

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Peritoneal Fluid

Download Full-text

Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer

Frontiers in Oncology ◽

10.3389/fonc.2021.590414 ◽

2021 ◽

Vol 11 ◽

Author(s):

Danian Dai ◽

Lili Liu ◽

He Huang ◽

Shangqiu Chen ◽

Bo Chen ◽

...

Keyword(s):

Ovarian Cancer ◽

T Cells ◽

Menopausal Status ◽

Tumor Infiltrating Lymphocytes ◽

Roc Curves ◽

Clinicopathological Characteristics ◽

High Grade ◽

Serous Ovarian Cancer ◽

Ki 67 ◽

Infiltrating Lymphocytes

BackgroundTumor-infiltrating lymphocytes (TILs) have important roles in predicting tumor therapeutic responses and progression, however, the method of evaluating TILs is complicated. We attempted to explore the association of TILs with clinicopathological characteristics and blood indicators, and to develop nomograms to predict the density of TILs in patients with high-grade serous ovarian cancer (HGSOC).MethodsThe clinical profiles of 197 consecutive postoperative HGSOC patients were retrospectively analyzed. Tumor tissues and matched normal fallopian tubes were immunostained for CD3+, CD8+, and CD4+ T cells on corresponding tissue microarrays and the numbers of TILs were counted using the NIH ImageJ software. The patients were classified into low- or high-density groups for each marker (CD3, CD4, CD8). The associations of the investigated TILs to clinicopathological characteristics and blood indicators were assessed and the related predictors for densities of TILs were used to develop nomograms; which were then further evaluated using the C-index, receiver operating characteristic (ROC) curves and calibration plots.ResultsMenopausal status, estrogen receptor (ER), Ki-67 index, white blood cell (WBC), platelets (PLT), lactate dehydrogenase (LDH), and carbohydrate antigen 153 (CA153) had significant association with densities of tumor-infiltrating CD3+, CD8+, or CD4+ T cells. The calibration curves of the CD3+ (C-index = 0.748), CD8+ (C-index = 0.683) and CD4+ TILs nomogram (C-index = 0.759) demonstrated excellent agreement between predictions and actual observations. ROC curves of internal validation indicated good discrimination for the CD8+ TILs nomogram [area under the curve (AUC) = 0.659, 95% CI 0.582–0.736] and encouraging performance for the CD3+ (AUC= 0.708, 95% CI 0.636–0.781) and CD4+ TILs nomogram (AUC = 0.730, 95% CI 0.659–0.801).ConclusionMenopausal status, ER, Ki-67 index, WBC, PLT, LDH, and CA153 could reflect the densities of T cells in the tumor microenvironment. Novel nomograms are conducive to monitor the immune status of patients with HGSOC and help doctors to formulate the appropriate treatment strategies.

Download Full-text

Intake of specific carotenoids and the risk of epithelial ovarian cancer

British Journal Of Nutrition ◽

10.1017/s0007114507690011 ◽

2007 ◽

Vol 98 (1) ◽

pp. 187-193 ◽

Cited By ~ 19

Author(s):

Min Zhang ◽

C. D'Arcy J. Holman ◽

Colin W. Binns

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Contraceptive Use ◽

Hormone Replacement ◽

Menopausal Status ◽

Ovarian Cancer Risk ◽

Total Carotenoids ◽

Oral Contraceptive Use ◽

Tea Drinking ◽

Β Carotene

There has been considerable interest in the role of carotenoids in the chemoprevention of cancer. However, few studies have examined the association between intake of specific carotenoids and the risk of epithelial ovarian cancer and the results for carotenoids have been inconclusive. To investigate whether the intake of α-carotene, β-carotene, β-cryptoxanthin, lutein and zeaxanthin, and lycopene is inversely associated with ovarian cancer risk, a case–control study was conducted in China during 1999–2000. The cases were 254 patients with histologically confirmed epithelial ovarian cancer and 652 age-matched controls were randomly recruited during the same period. Habitual dietary intake and lifestyle were collected by face-to-face interview using a validated and reliable FFQ. The US Department of Agriculture nutrient composition database was used to calculate the intake of specific carotenoids. Unconditional logistic regression analyses were used to estimate OR and 95 % CI, accounting for age, locality, education, BMI, smoking, tea drinking, parity, oral contraceptive use, hormone replacement therapy, menopausal status, family history of ovarian cancer, physical activity and energy intake. Compared with the highest v. the lowest quartile of intake, the adjusted OR were 0·39 (95 % CI 0·23, 0·66) for α-carotene, 0·51 (95 % CI 0·31, 0·84) for β-carotene, 0·51 (95 % CI 0·31, 0·83) for β-cryptoxanthin, 0·45 (0·27, 0·76) for lutein and zeaxanthin, and 0·33 (95 % CI 0·20, 0·56) for total carotenoids, with statistically significant tests for trend. It is concluded that a higher intake of carotenoids can reduce the risk of epithelial ovarian cancer.

Download Full-text

A Mother in Jeopardy: The Ethics of Pregnancy and Chemotherapy

American Journal of Hospice and Palliative Medicine® ◽

10.1177/1049909119846861 ◽

2019 ◽

Vol 37 (1) ◽

pp. 72-78

Author(s):

Steven J. Baumrucker ◽

Wendy H. Vogel ◽

Robert M. Stolick ◽

Russell W. Adkins ◽

Heather Holland ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Ovarian Cyst ◽

Peritoneal Fluid ◽

Polycystic Ovary ◽

Advanced Stage ◽

Ovarian Mass ◽

Prenatal Visit ◽

The Past ◽

Fluid Cytology

JM is a 32-year-old primagravida with polycystic ovary disease. She had extreme difficulty conceiving and was started on clomiphene 6 months ago by her fertility specialist. After doubling the dose on the sixth cycle, she successfully became pregnant. On her second prenatal visit at 12 weeks gestation, an ovarian cyst was detected. Ultrasound showed a complex ovarian mass with nodules on the bowel and abdominal wall. There was mild-to-moderate peritoneal fluid. Cytology showed adenocarcinoma of ovarian origin. Further workup demonstrated advanced stage III epithelial ovarian cancer. JM was referred to GYN-oncology who felt pregnancy-sparing debulking was not an option. The oncologist recommended termination of pregnancy due to the risks of delaying chemotherapy. JM refused, citing her fertility difficulties in the past and her desire to carry the pregnancy to term “even if it kills me.” She tells the oncologist she cannot bear the thought of terminating her pregnancy under any circumstances. The oncologist wants to comply with her wishes but feels the patient is making a choice that would result in harm to herself. The oncology team requests an ethics consult.

Download Full-text